Chris Davis's Strategic Acquisition of Viatris Inc. Shares

Chris Davis (Trades, Portfolio) significantly increased his firm's stake in Viatris Inc. on September 30, 2025, acquiring 2,970,125 shares at $9.90 each, which boosted Viatris to 3.67% of the portfolio. This strategic move by Davis Advisors, known for its long-term value investing in well-managed businesses, signals confidence in the pharmaceutical company despite its current challenges, including a -13.69% YTD performance and a "poor future performance potential" GF Score of 66/100. The transaction underscores Davis's belief in Viatris's ability to navigate market hurdles and deliver value, positioning Davis Selected Advisers as the largest holder among notable investors in the $12.35 billion market cap generic and specialty drug maker.

Analysis

Chris Davis (Trades, Portfolio) significantly increased his firm's stake in Viatris Inc. (VTRS) on September 30, 2025, acquiring 2,970,125 shares at $9.90 each. This transaction boosted Viatris to 3.67% of the firm's portfolio, reflecting a strategic decision aligned with Davis Advisors' long-term value investing philosophy of acquiring well-managed businesses when they are potentially undervalued or out of favor. Davis Selected Advisers now holds the largest share among notable investors in Viatris.

Viatris, formed in 2020, is a pharmaceutical powerhouse with a $12.35 billion market capitalization, specializing in generics, biosimilars (40% of sales), and legacy products like Lipitor and Viagra (60% of sales). Despite its market presence and focus on future innovations in dermatology, ophthalmology, and gastroenterology, the company faces significant performance challenges.

The company's stock has seen a -13.69% year-to-date price change and a -5.80% 3-year revenue growth decline. Its GF Score of 66/100 indicates poor future performance potential, with moderate profitability (5/10) and balance sheet (4/10) ranks. Davis's investment, despite these metrics and the stock being considered fairly valued at $10.72 against a GF Value of $10.05, underscores a strong conviction in Viatris's ability to navigate market hurdles and deliver value over the long term, consistent with their contrarian approach.

Key Decisions for Investors

• Investors should consider Chris Davis's significant Viatris stake increase as a contrarian signal, suggesting potential long-term value despite current underperformance.
• Monitor Viatris's strategic initiatives in dermatology, ophthalmology, and gastroenterology, alongside improvements in its profitability and balance sheet ranks, for signs of fundamental turnaround.
• Evaluate VTRS through a long-term value investment lens, acknowledging its current challenges and the potential for future recovery if management successfully executes on its strategic objectives.